Hepatocellular Carcinoma
Conditions
Interventions
Regular dose group:GPC3-03-ICG fluorescent probe, 1.5 mg/kg, single peripheral intravenous administration
Low dose group:GPC3-03-ICG fluorescent probe, 0.75 mg/kg, single peripheral intravenous administration
Sponsors
Zhongshan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.18 years = 50 × 10^9/L ; 12. The patient has provided informed consent;
Exclusion criteria
Exclusion criteria: 1.Severe abdominal adhesions precluding laparoscopic surgery; 2.Unstable angina, myocardial infarction, cerebrovascular accident, uncontrolled epilepsy, CNS disorders, or severe psychiatric illness within the past 6 months ; 3.Severe, uncontrolled recurrent infections or other severe uncontrolled concomitant diseases; 4.Chronic systemic corticosteroid therapy or immunosuppressive therapy; 5.Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Accuracy;Positive rate of fluorescent staining for hepatocellular carcinoma; | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety; | — |
Countries
China
Contacts
Public ContactWang Xiaoying
Zhongshan Hospital, Fudan University
Outcome results
None listed